Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fusion Clear all
Active, not recruiting Phase 3 Interventional

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

NCT04768972
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ION363, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
10 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
La Jolla, California • Palo Alto, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 24, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

NCT04161495
View directory record Official record
Conditions
Factor VIII Deficiency
Interventions
efanesoctocog alfa (BIVV001)
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
12 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 24, 2026, 6:01 PM EDT
Recruiting Phase 2 Interventional

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

NCT05307939
View directory record Official record
Conditions
HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B)
Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 6:01 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma

NCT01610570
View directory record Official record
Conditions
Ewing Sarcoma, Sarcoma
Interventions
Mithramycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 24, 2026, 6:01 PM EDT
Recruiting Phase 1 Interventional

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

NCT04248569
View directory record Official record
Conditions
Fibrolamellar Hepatocellular Carcinoma (FLC)
Interventions
DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 24, 2026, 6:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)

NCT06462729
View directory record Official record
Conditions
Degenerative Disc Disease, Lumbar Disc Disease, Spine Disease, Lumbar Spine Degeneration
Interventions
LDGraft, Allograft Bone
Device · Other
Lead sponsor
Locate Bio Pty Ltd
Industry
Eligibility
22 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Fort Wayne, Indiana • Pinehurst, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 24, 2026, 6:01 PM EDT
Enrolling by invitation Phase 4 Interventional

Prospective Opioid-Free AIS Fusion

NCT06935331
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis (AIS)
Interventions
Opioid-Free/Opioid-Avoidant, Opioid-Containing
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
10 Years to 20 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 24, 2026, 6:01 PM EDT
Completed Phase 1 Interventional

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

NCT05524545
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma
Interventions
Evorpacept, Enfortumab Vedotin
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Tampa, Florida • Boston, Massachusetts • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 24, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents

NCT00022763
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Years to 16 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Los Angeles, California • Gainesville, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 24, 2026, 6:01 PM EDT
Completed Phase 2 Interventional

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

NCT00001564
View directory record Official record
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
EF-1 Peptide, EF-2 Peptide, PXFK Peptide, E7 Peptide, IL-2, IL-4, GM-CSF, CD40 Ligand
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 24, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

NCT00587964
View directory record Official record
Conditions
Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma, Testicular Cancer
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 24, 2026, 6:01 PM EDT
Terminated Phase 1 Interventional

Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

NCT04901806
View directory record Official record
Conditions
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
Interventions
PBI-200
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Santa Monica, California • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 24, 2026, 6:01 PM EDT
Not listed Not applicable Interventional

Baxter: Actifuse SHAPE vs DBX in ACC

NCT02005081
View directory record Official record
Conditions
Cervical Spine Degenerative Disease Nos, Cervical Spondylosis With Myelopathy
Interventions
Actifuse SHAPE, Autograft with Demineralized Bone Matrix
Device
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Oct 24, 2026, 6:01 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

NCT05038592
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
Decitabine, Tagraxofusp-erzs
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 24, 2026, 6:01 PM EDT
Completed Not applicable Interventional

A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System

NCT00678171
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
TLIF with a PEEK Spacer System and XIA Spinal System
Device
Lead sponsor
Olympus Biotech Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Durango, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Oct 24, 2026, 6:01 PM EDT
Completed No phase listed Observational

Fusion Assessment Clinical Trial

NCT00736398
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Spinal fusion
Procedure
Lead sponsor
Flexuspine, Inc.
Industry
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
6
States / cities
Clearwater, Florida • Temple Terrace, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 24, 2026, 6:01 PM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

NCT04789044
View directory record Official record
Conditions
Peripheral Nerve Injuries
Interventions
NTX-001
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Baltimore, Maryland • Camden, New Jersey • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 24, 2026, 6:01 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion

NCT02424591
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

NCT01972568
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 milligram (mg), Atacicept 150 mg, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
30
States / cities
Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 24, 2026, 6:01 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion

NCT01430299
View directory record Official record
Conditions
Stenosis, Spondylosis, Degenerative Changes
Interventions
Demineralized Bone Matrix, rh-BMP2
Device
Lead sponsor
SeaSpine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 24, 2026, 6:01 PM EDT
Terminated Phase 4 Interventional

Comparison of Actifuse ABX and Local Bone in Spinal Surgery

NCT01852747
View directory record Official record
Conditions
Scoliosis, Kyphosis, Lordosis
Interventions
Multilevel Spinal fusion with Actifuse ABX®
Procedure
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 24, 2026, 6:01 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 24, 2026, 6:01 PM EDT
Terminated No phase listed Observational

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

NCT02392156
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
rFVIIIFc, rFIXFc, non-Fc FVIII replacement products, non-Fc FIX replacement products
Biological · Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Los Angeles, California • East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 24, 2026, 6:01 PM EDT
Enrolling by invitation Not applicable Interventional

Optimizing Bilateral and Single-sided-deafness Cochlear Implants for Functioning in Complex Auditory Environments

NCT06305039
View directory record Official record
Conditions
Hearing Loss, Hearing Loss, Sensorineural, Cochlear Hearing Loss
Interventions
Diagnostic tests of cochlear implant or acoustic hearing function, Targeted aural rehabilitation of the poorer performing ear
Diagnostic Test · Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 24, 2026, 6:01 PM EDT